



Zai Lab Awarded Commercial Achievement of the Year

November 22, 2019

SHANGHAI, China, November 21, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that they have received the Commercial Achievement of the Year Award at the 10th Annual BayHelix Awards Lunch Banquet held during the annual BioCentury-BayHelix China Healthcare Summit in Shanghai, China.

The annual award recognizes a creative model that delivered superior value to patients/payers in China and commercial success. Zai Lab is awarded for the launch of Zejula (niraparib) in Hong Kong and Macau, which is a first for the company, representing its transition into a fully integrated biopharmaceutical company.

Since the Hong Kong launch of ZEJULA in October 2018, it has rapidly gained market share in the region despite being launched more than two years behind its competitor. Based on IQVIA data*, ZEJULA is now the market leading PARP inhibitor with market share in Hong Kong of 77% in the third quarter of 2019. Since officially launched in February 2019, Optune's revenue has ramped ahead of expectations, with strong momentum generated for the second half of the year.

"Thanks Bayhelix for awarding Zai Lab 'the commercial achievement of the year', which is a strong recognition about our commercial capability. This award is not only to celebrate the commercial success, but also to memorize the patients we have helped in Hong Kong and Macau," said William Liang, Chief Commercial Officer, "This is just a start, we will work closely with the regulatory authority in mainland China to get Zejula and Optune approved as fast as possible, more patients are waiting for us and we are looking forward to helping more of them in future."

** IQVIA Hong Kong Pharmaceutical Audit QTR 3Q2019 data*

About Zai Lab

Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The Company's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and global unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

About BayHelix

BayHelix is an organization of leaders of Chinese heritage in the global life sciences and health care community. BayHelix China Healthcare Awards are presented each year in five categories: R&D Achievement of Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year. This is the fifth award that Zai Lab has received from BayHelix. In 2014, Zai La received China Pharmaceutical Awards-Alliance of the year. In 2016 and 2017, Dr. Samantha Du received the Person of the Year and Lifetime Achievement awards, respectively. In 2017, Zai Lab received the Company of the Year award. In 2018, Zai Lab also received the Deal of the Year award.

About Zejula (niraparib)

Niraparib is a highly potent and selective oral, once-daily small molecule poly (ADP-ribose) PARP 1/2 inhibitor. Zai Lab in-licensed rights to Zejula (niraparib) from GSK for China, Hong Kong and Macau as an important, new treatment option for more than 52,000 Chinese patients who suffer from ovarian cancer every year. It was approved in March 2017 by the FDA in the United States and in November 2017 by the EMA in the European Union under the trade name Zejula as a maintenance treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Based on the approval status in the United States and European Union by our partner, GSK, Zai Lab obtained the approval for marketing Zejula in Hong Kong in October 2018 and Macau in June 2019.

About Tumor Treating Fields

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. Tumor Treating Fields does not stimulate or heat tissue and targets dividing cancer cells of a specific size. Tumor Treating Fields causes minimal damage to healthy cells. Mild to moderate skin irritation is the most common side effect reported. Tumor Treating Fields is approved in certain countries for the treatment of adults with glioblastoma and mesothelioma, two of the most difficult cancer types to treat. The therapy shows promise in multiple solid tumor types – including some of the most aggressive forms of cancer.